

# **BCLC™ AKG-PQQ-Agaricus bisporus Triad for Mitochondrial Function Support: Formulation Engineering and Evidence in Senescent Hepatocytes**

Nour-Eddine Ziraoui\*, Rafael Mendoza, Victoria Harrington, Sofia Carter

National Standards Laboratory SA, Chemin des Orlons 10 CH-1860 Aigle, Switzerland

\*Corresponding Author: [info@ns-lab.ch](mailto:info@ns-lab.ch)

## **ABSTRACT**

Background: Mitochondrial dysfunction is increasingly recognized as a central feature of cellular senescence and age-related functional decline [1, 2]. Objective: We evaluated a ratio-defined triad containing alpha-ketoglutarate (AKG), pyrroloquinoline quinone disodium (PQQ), and Agaricus bisporus extract, and we aligned the formulation dataset with published mechanistic and human evidence relevant to mitochondrial support. Methods: We summarized composition windows, post-processing retention, and 48 h senescent-hepatocyte readouts, then compared these data with peer-reviewed studies on mitochondrial biogenesis, redox control, and mushroom-derived ergothioneine bioavailability [3-13]. Results: Across the three embodiments, AKG and PQQ retention remained high after processing (98.6-99.2%), while the comparative formula showed lower retention (92.2-92.8%). In senescent hepatocytes, the comparative formula showed lower membrane potential (52.3-65.2% of embodiment values) and higher mitochondrial reactive oxygen species (2.1-2.5-fold versus embodiments). Public evidence supported the mechanistic plausibility of the triad: PQQ has repeatedly been linked with mitochondrial biogenesis signaling [3-8]; AKG has shown protection against mitochondrial dysfunction and oxidative stress in hepatocyte-based models [9]; and ergothioneine from A. bisporus is bioavailable in humans and is increasingly linked with oxidative-stress resilience [11-13]. Conclusion: The triad shows coherent formulation-performance characteristics and biologically plausible multi-target activity, but dedicated human trials of the specific combined system are still required.

## **KEYWORDS**

AKG; PQQ; Agaricus bisporus; Ergothioneine; Beta-glucan; Mitochondria; Membrane potential; ROS; Dry granulation; Senescence

## **1. INTRODUCTION**

The biological relevance of mitochondrial dysfunction to aging is now well established. Mitochondrial dysfunction and cellular senescence are closely interconnected, and the senescent phenotype is typically accompanied by lower mitochondrial membrane potential, impaired respiratory capacity, and increased reactive oxygen species (ROS) generation [1]. At the population level, the need for interventions that support healthy aging continues to grow: the World Health Organization estimates that the number of people aged 60 years and older will rise from 1.0 billion in 2019 to 1.4 billion by 2030 and 2.1 billion by 2050 [2].

In this context, multi-component nutritional systems that address mitochondrial substrate supply, biogenesis signaling, and redox defense may offer a more coherent strategy than single-mechanism products. In the present work, we examine a triad composed of AKG, PQQ disodium, and Agaricus

bisporus extract. AKG contributes a tricarboxylic-acid-cycle intermediate relevant to mitochondrial metabolism; PQQ has been associated with SIRT1/PGC-1alpha and AMPK-linked mitochondrial biogenesis pathways [3-5]; and A. bisporus provides mushroom-derived bioactives, particularly ergothioneine and beta-glucan-associated fractions, that may support redox buffering and membrane resilience [11-13].

Our goal was to present a polished scholarly manuscript that preserves the core formulation and cell-model dataset while anchoring the interpretation in published evidence. Rather than treating the formulation data in isolation, we examined whether current literature supports the mechanistic logic of this triad and where the evidentiary gaps remain.

## 2. MATERIALS AND METHODS

We evaluated a formulation dataset containing composition windows, extraction and dry-granulation parameters, active-ingredient retention after processing, and 48 h readouts from senescent-model hepatocytes. The three embodiments used AKG at 45.0-60.0 parts, PQQ disodium at 0.2-0.5 parts, Agaricus bisporus extract at 19.6-34.5 parts, and a single food-grade excipient at 20.0 parts. The comparative formulation omitted the mushroom extract and used multiple excipients.

To place these findings in context, we conducted a targeted literature review focused on four domains: (i) mitochondrial dysfunction and senescence; (ii) PQQ-related mitochondrial biogenesis and human supplementation data; (iii) AKG-related mitochondrial and redox biology, especially in liver-relevant models; and (iv) mushroom-derived ergothioneine and A. bisporus bioavailability. Only citable public sources were retained in the evidence table and references.

**Table 1.** Composition and extract attributes across embodiments

| Group        | AKG  | PQQ | A. bisporus extract | Excipient (s)                    | Excipient (parts) | beta-glucan (%) | Ergothioneine (%) | Loss on drying (%) | Water-soluble extractives (%) |
|--------------|------|-----|---------------------|----------------------------------|-------------------|-----------------|-------------------|--------------------|-------------------------------|
| Embodiment 1 | 50.0 | 0.2 | 29.8                | Mannitol                         | 20.0              | 20.0            | 0.005             | 3.0                | 45.0                          |
| Embodiment 2 | 60.0 | 0.4 | 19.6                | Lactose                          | 20.0              | 28.0            | 0.008             | 2.5                | 48.0                          |
| Embodiment 3 | 45.0 | 0.5 | 34.5                | Microcrystalline cellulose       | 20.0              | 25.0            | 0.009             | 4.0                | 46.0                          |
| Comparative  | 52.0 | 0.3 | -                   | Mannitol + lactose + Mg stearate | 17.7              | -               | -                 | 2.5                | -                             |

**Table 2.** Post-processing active-ingredient retention

| Group        | AKG retention (%) | PQQ retention (%) | Extract retention (%) |
|--------------|-------------------|-------------------|-----------------------|
| Embodiment 1 | 98.6              | 98.9              | 98.4                  |
| Embodiment 2 | 98.7              | 99.1              | 98.5                  |
| Embodiment 3 | 98.9              | 99.2              | 98.8                  |
| Comparative  | 92.2              | 92.8              | -                     |


**Table 3.** Comparative performance in senescent hepatocytes

| Comparison                  | Membrane potential (% of embodiment) | ROS (fold vs embodiment) |
|-----------------------------|--------------------------------------|--------------------------|
| Comparative vs Embodiment 1 | 65.2                                 | 2.1                      |
| Comparative vs Embodiment 2 | 58.7                                 | 2.3                      |
| Comparative vs Embodiment 3 | 52.3                                 | 2.5                      |


### 3. RESULTS

The formulation dataset showed strong manufacturing retention for the active triad. AKG retention ranged from 98.6% to 98.9%, PQQ retention from 98.9% to 99.2%, and extract retention from 98.4% to 98.8% across the three embodiments, whereas the comparative formula yielded only 92.2% AKG retention and 92.8% PQQ retention. These values are consistent with the proposed single-excipient, low-interaction process logic.


Cell-model outcomes were directionally consistent with improved mitochondrial resilience. Relative to each embodiment, the comparative formula exhibited substantially lower mitochondrial membrane potential and markedly higher mitochondrial ROS after 48 h exposure in senescent hepatocytes. The magnitude of difference was largest when the comparative formula was benchmarked against Embodiment 3, suggesting that the broader active window and retained mushroom fraction may contribute to the observed performance profile.




**Figure 1.** Active-ingredient retention after processing



**Figure 2.** Comparative performance versus embodiments in senescent hepatocytes



**Figure 3.** Active composition windows across embodiments



**Figure 4.** Proposed multi-dimensional mitochondrial-support framework

Published evidence further strengthened the interpretation of the triad. PQQ has been shown to stimulate mitochondrial biogenesis in mouse hepatocytes and fibroblasts, including increased mtDNA-related signals and activation of the SIRT1/PGC-1 $\alpha$  axis [4, 5]. In HepG2 cells, PQQ increased Sirt1 and Sirt3 expression and activity [3]. Additional work in stress-induced premature senescence models reported recovery of mitochondrial function and biogenesis under PQQ exposure [6]. Human studies are more heterogeneous: randomized trials have reported improvements in mitochondrial biomarkers, cognition, or both in selected older populations [7, 8], whereas a 6-week exercise study in untrained men did not show a significant performance advantage despite the mechanistic rationale [9].

AKG-related evidence is strongest in mechanistic and preclinical settings. In a 2024 Redox Biology study, AKG attenuated mitochondrial dysfunction, oxidative stress, and lipid-associated hepatocyte injury in mice, HepG2 cells, and primary hepatocytes through the AMPK-PGC-1 $\alpha$ /Nrf2 pathway [10]. By contrast, human geroprotective evidence for AKG remains limited; the published ABLE protocol explicitly notes that few studies have tested AKG in humans [11]. For the mushroom arm of the triad, ergothioneine from *A. bisporus* was shown in a randomized human study to be bioavailable, with postprandial uptake into red blood cells [12]. Broader review and pilot-trial literature increasingly links ergothioneine with oxidative-stress resilience, preserved mitochondrial function, and favorable cognitive biomarkers, although long-term confirmation is still needed [13, 14].

**Table 4.** Published evidence aligned with the triad logic.

| Evidence domain                          | Study type                              | Main findings                                                                                                                                         | Relevance to present system                                                       | Refs    |
|------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------|
| Mitochondrial dysfunction and senescence | Review                                  | Reduced membrane potential and increased ROS are core features of senescent cells.                                                                    | Supports the relevance of the membrane-potential and ROS endpoints measured here. | [1]     |
| PQQ mechanistic signaling                | Cell and animal studies                 | PQQ promoted mitochondrial biogenesis and activated SIRT1/PGC-1alpha or AMPK-linked pathways.                                                         | Supports the biogenesis-signaling arm of the triad.                               | [3-6]   |
| PQQ human evidence                       | Randomized trials                       | Signals for improved mitochondrial biomarkers, cognition, or both in selected populations, but not uniformly across all outcomes.                     | Supports translational plausibility while highlighting heterogeneity.             | [7-9]   |
| AKG liver-relevant evidence              | Mouse, HepG2, and primary hepatocytes   | AKG attenuated mitochondrial dysfunction, ROS, and redox imbalance via AMPK-PGC-1alpha/Nrf2.                                                          | Supports the metabolic-substrate and redox arm of the triad.                      | [10]    |
| AKG human evidence                       | Intervention protocol                   | Published investigators explicitly note that human geroprotective evidence remains limited.                                                           | Supports cautious interpretation of clinical relevance.                           | [11]    |
| A. bisporus / ergothioneine evidence     | Human bioavailability study and reviews | Ergothioneine from A. bisporus is bioavailable; broader literature links ergothioneine with oxidative-stress resilience and mitochondrial protection. | Supports inclusion of the mushroom extract as a biologically active arm.          | [12-14] |

## 4. DISCUSSION

Taken together, the results support a system-level interpretation rather than a single-ingredient explanation. AKG plausibly supports metabolic substrate handling and mitochondrial redox homeostasis; PQQ contributes the strongest biogenesis-signaling literature; and the mushroom fraction adds a dietary antioxidant axis centered on ergothioneine, with beta-glucan-rich extracts offering additional biological activity. The single-excipient manufacturing strategy may also matter practically because higher retention reduces the risk that nominal label composition diverges from delivered active composition.

We also note that the public evidence is uneven across the three components. PQQ has the most direct mitochondrial-signaling literature, AKG has a convincing liver-relevant preclinical signal but limited human validation, and A. bisporus-related evidence is strongest for ergothioneine bioavailability and antioxidant relevance rather than for direct demonstration of mitochondrial membrane-potential rescue in humans. Accordingly, the strongest conclusion supported by the present manuscript is not that the triad has already proven anti-aging efficacy in humans, but that its formulation logic and in vitro profile are scientifically coherent and aligned with the direction of the broader literature.

The next step should be prospective clinical evaluation of the specific combined system. Appropriate endpoints would include circulating and cellular redox markers, mitochondrial functional biomarkers,

cognition- or fatigue-related patient-reported outcomes, and safety measurements collected over a sufficiently long follow-up period. Until such trials are completed, the present manuscript is best interpreted as a formulation-centered evidence paper with a supportive, not definitive, translational claim.

## 5. CONCLUSION

In summary, the BCLC triad combining AKG, PQQ disodium, and *Agaricus bisporus* extract demonstrated high post-processing retention and favorable mitochondrial readouts in senescent hepatocytes. When interpreted alongside current literature, the triad reflects a plausible multi-target strategy for mitochondrial support that deserves direct clinical testing.

## REFERENCES

- [1] Miwa S, Kashyap S, Chini E, von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. *J Clin Invest*. 2022; 132(13):e158447.
- [2] World Health Organization. Ageing. WHO Health Topics. Updated 2025.
- [3] Zhang J, et al. Pyrroloquinoline quinone increases the expression and activity of Sirt1 and Sirt3 in HepG2 cells. *Nutrition*. 2015; 31(10):1297-1303.
- [4] Chowanadisai W, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through CREB phosphorylation and increased PGC-1 $\alpha$  expression. *J Biol Chem*. 2010; 285(1):142-152.
- [5] Saihara K, et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1 $\alpha$  signaling pathway. *J Nutr Biochem*. 2017; 40:107-120.
- [6] Gao Y, et al. Pyrroloquinoline quinone protects mitochondrial function under premature senescence by restoring SIRT1/PGC-1 $\alpha$  signaling. *npj Aging*. 2022; 8:17.
- [7] Baltic S, et al. The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial. *J Nutr Health Aging*. 2024; 28:100287.
- [8] Shiojima Y, et al. Effect of dietary pyrroloquinoline quinone disodium salt on cognitive function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. *Food Style* 21. 2022; 26(4):573-583.
- [9] Hwang PS, et al. Effects of pyrroloquinoline quinone supplementation on aerobic exercise performance and indices of mitochondrial biogenesis in untrained men. *J Am Coll Nutr*. 2020; 39(7):641-651.
- [10] Cheng D, et al.  $\alpha$ -Ketoglutarate prevents hyperlipidemia-induced fatty liver mitochondrial dysfunction and oxidative stress by activating the AMPK-PGC-1 $\alpha$ /Nrf2 pathway. *Redox Biol*. 2024; 74:103230.
- [11] Sandalova E, et al. Alpha-ketoglutarate supplementation and Biological age in middle-aged adults (ABLE): intervention study protocol. *Front Aging*. 2023; 4:1110875.
- [12] Weigand-Heller ABJ, Kris-Etherton PM, Beelman RB. The bioavailability of ergothioneine from mushrooms (*Agaricus bisporus*) and the acute effects on antioxidant capacity and biomarkers of inflammation. *Prev Med*. 2012; 54 (Suppl): S75-S78.
- [13] Borodina I, et al. The biology of ergothioneine, an antioxidant nutraceutical. *J Nutr Sci*. 2020; 9:e52.
- [14] Yau YF, et al. Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: a pilot study. *J Alzheimers Dis*. 2024; 102(3):841-854.